Identification of key target genes and pathway analysis in nonalcoholic fatty liver disease via integrated bioinformatics analysis

1Erman H, Beydogan E, Cetin SI, Boyuk B. Endocan: A Biomarker for Hepatosteatosis in Patients with Metabolic Syndrome. Mediators Inflamm. 2020; 2020: 3534042.Erman H Beydogan E Cetin SI Boyuk B Endocan: A Biomarker for Hepatosteatosis in Patients with Metabolic Syndrome Mediators Inflamm 2020 2020 353404210.1155/2020/3534042715297832317862Search in Google Scholar

2Aizawa M, Inagaki S, Moriyama M, Asano K, Kakehashi M. Modeling the natural history of fatty liver using lifestyle-related risk factors: Effects of body mass index (BMI) on the life-course of fatty liver. PLoS One. 2019; 14(10):e0223683.Aizawa M Inagaki S Moriyama M Asano K Kakehashi M Modeling the natural history of fatty liver using lifestyle-related risk factors: Effects of body mass index (BMI) on the life-course of fatty liver PLoS One 2019 1410e022368310.1371/journal.pone.0223683680283731634357Search in Google Scholar

3Zelber-Sagi S, Lotan R, Shlomai A, Webb M, Harrari G, Buch A, et al. Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up. Journal of hepatology. 2012; 56(5): 1145-1151.Zelber-Sagi S Lotan R Shlomai A Webb M Harrari G Buch A et al Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up Journal of hepatology 2012 565 1145 115110.1016/j.jhep.2011.12.01122245895Search in Google Scholar

4Sookoian S, Pirola CJ. Review article: shared disease mechanisms between non-alcoholic fatty liver disease and metabolic syndrome - translating knowledge from systems biology to the bedside. Aliment Pharmacol Ther. 2019; 49(5): 516-527.Sookoian S Pirola CJ Review article: shared disease mechanisms between non-alcoholic fatty liver disease and metabolic syndrome - translating knowledge from systems biology to the bedside Aliment Pharmacol Ther 2019 495 516 52710.1111/apt.1516330714632Search in Google Scholar

5Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018; 24(7):908-922.Friedman SL Neuschwander-Tetri BA Rinella M Sanyal AJ Mechanisms of NAFLD development and therapeutic strategies Nat Med 2018 247908 92210.1038/s41591-018-0104-9655346829967350Search in Google Scholar

6Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015; 313(22):2263-73.Rinella ME Nonalcoholic fatty liver disease: a systematic review JAMA 2015 313222263 7310.1001/jama.2015.537026057287Search in Google Scholar

7Noureddin M, Rinella ME. Nonalcoholic Fatty liver disease, diabetes, obesity, and hepatocellular carcinoma. Clin Liver Dis. 2015; 19(2):361-79.Noureddin M Rinella ME Nonalcoholic Fatty liver disease, diabetes, obesity, and hepatocellular carcinoma Clin Liver Dis 2015 192361 7910.1016/j.cld.2015.01.012665817125921668Search in Google Scholar

8Fabbrini E, Magkos F, Mohammed BS, Pietka T, Abumrad NA, Patterson BW, et al. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci USA. 2009;106(36):15430-5.Fabbrini E Magkos F Mohammed BS Pietka T Abumrad NA Patterson BW et al Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity Proc Natl Acad Sci USA 20091063615430 510.1073/pnas.0904944106274126819706383Search in Google Scholar

9Konerman MA, Jones JC, Harrison SA. Pharmacotherapy for NASH: Current and emerging. J Hepatol. 2018; 68(2):362-375.Konerman MA Jones JC Harrison SA Pharmacotherapy for NASH: Current and emerging J Hepatol 2018 682362 37510.1016/j.jhep.2017.10.01529122694Search in Google Scholar

10Sookoian S, Rosselli MS, Gemma C, Burgueño AL, Fernández Gianotti T, Castaño GO, Pirola CJ. Epigenetic regulation of insulin resistance in nonalcoholic fatty liver disease: impact of liver methylation of the peroxisome proliferator-activated receptor γ coactivator 1α promoter. Hepatology. 2010; 52(6):1992-2000Sookoian S Rosselli MS Gemma C Burgueño AL Fernández Gianotti T Castaño GO Pirola CJ Epigenetic regulation of insulin resistance in nonalcoholic fatty liver disease: impact of liver methylation of the peroxisome proliferator-activated receptor γ coactivator 1α promoter Hepatology 2010 5261992 200010.1002/hep.2392720890895Search in Google Scholar

11Liu NK, Xu XM. MicroRNA in central nervous system trauma and degenerative disorders. Physiol Genomics. 2011; 43(10):571-80Liu NK Xu XM MicroRNA in central nervous system trauma and degenerative disorders Physiol Genomics 2011 4310571 8010.1152/physiolgenomics.00168.2010311089121385946Search in Google Scholar

12Piazzolla VA, Mangia A. Noninvasive Diagnosis of NAFLD and NASH. Cells. 2020; 9(4):1005Piazzolla VA Mangia A Noninvasive Diagnosis of NAFLD and NASH Cells 2020 94100510.3390/cells9041005722647632316690Search in Google Scholar

13Zou B, Yeo YH, Nguyen VH, Cheung R, Ingelsson E, Nguyen MH. Prevalence, characteristics and mortality outcomes of obese, nonobese and lean NAFLD in the United States, 1999-2016. J Intern Med. 2020; 288(1):139-151Zou B Yeo YH Nguyen VH Cheung R Ingelsson E Nguyen MH Prevalence, characteristics and mortality outcomes of obese, nonobese and lean NAFLD in the United States, 1999-2016 J Intern Med 2020 2881139 15110.1111/joim.1306932319718Search in Google Scholar

14Lefebvre P, Lalloyer F, Baugé E, Pawlak M, Gheeraert C, Dehondt H, et al. Interspecies NASH disease activity whole-genome profiling identifies a fibrogenic role of PPARα-regulated dermatopontin. JCI Insight. 2017 Jul 6;2(13):e92264Lefebvre P Lalloyer F Baugé E Pawlak M Gheeraert C Dehondt H et al Interspecies NASH disease activity whole-genome profiling identifies a fibrogenic role of PPARα-regulated dermatopontin JCI Insight 2017 Jul 6213e9226410.1172/jci.insight.92264549937028679947Search in Google Scholar

15Barrett T, Troup DB, Wilhite SE, Ledoux P, Rudnev D, Evangelista C, et al. NCBI GEO: mining tens of millions of expression profiles--database and tools update. Nucleic Acids Res. 2007; 35(Database issue):D760-5Barrett T Troup DB Wilhite SE Ledoux P Rudnev D Evangelista C et al NCBI GEO: mining tens of millions of expression profiles--database and tools update Nucleic Acids Res 2007 35Database issueD760 510.1093/nar/gkl887166975217099226Search in Google Scholar

16Braschi B, Denny P, Gray K, Jones T, Seal R, Tweedie S, et al. Genenames.org: the HGNC and VGNC resources in 2019. Nucleic Acids Res. 2019; 47(D1):D786-D792Braschi B Denny P Gray K Jones T Seal R Tweedie S et al Genenames.org: the HGNC and VGNC resources in 2019. Nucleic Acids Res 2019; 47D1D786 D79210.1093/nar/gky930632405730304474Search in Google Scholar

17Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015; 43 (7):e47Ritchie ME Phipson B Wu D Hu Y Law CW Shi W Smyth GK limma powers differential expression analyses for RNA-sequencing and microarray studies Nucleic Acids Res 2015 43 7e4710.1093/nar/gkv007440251025605792Search in Google Scholar

18Wang L, Cao C, Ma Q, Zeng Q, Wang H, Cheng Z, et al. RNA-seq analyses of multiple meristems of soybean: novel and alternative transcripts, evolutionary and functional implications. BMC Plant Biol. 2014; 14:169Wang L Cao C Ma Q Zeng Q Wang H Cheng Z et al RNA-seq analyses of multiple meristems of soybean: novel and alternative transcripts, evolutionary and functional implications BMC Plant Biol 2014 1416910.1186/1471-2229-14-169407008824939556Search in Google Scholar

19Bonow RO. Braunwald` s Heart Disease: A Textbook of Cardiovascular Medicine, Single Volume, 9<sup>th</sup> Edition.Bonow RO Braunwald` s Heart Disease: A Textbook of Cardiovascular Medicine, Single Volume, 9^th EditionSearch in Google Scholar

20Szekely, G., Rizzo, M. Hierarchical Clustering via Joint Between-Within Distances: Extending Ward’s Minimum Variance Method. Journal of Classification; 2005; 22, 151–183Szekely G. Rizzo M Hierarchical Clustering via Joint Between-Within Distances: Extending Ward’s Minimum Variance Method Journal of Classification 2005 22 151–18310.1007/s00357-005-0012-9Search in Google Scholar

21Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009; 4(1):44-57Huang da W Sherman BT Lempicki RA Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources Nat Protoc 2009 4144 5710.1038/nprot.2008.21119131956Search in Google Scholar

22Huang da W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009; 37(1):1-13Huang da W Sherman BT Lempicki RA Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists Nucleic Acids Res 2009 3711 1310.1093/nar/gkn923261562919033363Search in Google Scholar

23Huang Z, Shi J, Gao Y, Cui C, Zhang S, Li J, et al. HMDD v3.0: a database for experimentally supported human microRNA-disease associations. Nucleic Acids Res. 2019; 47(D1):D1013-D1017Huang Z Shi J Gao Y Cui C Zhang S Li J et al HMDD v3.0: a database for experimentally supported human microRNA-disease associations Nucleic Acids Res 2019 47D1D1013 D101710.1093/nar/gky1010632399430364956Search in Google Scholar

24Paraskevopoulou MD, Vlachos IS, Karagkouni D, Georgakilas G, Kanellos I, Vergoulis T, et al. DI-ANA-LncBase v2: indexing microRNA targets on non-coding transcripts. Nucleic Acids Res. 2016; 44(D1):D231-8Paraskevopoulou MD Vlachos IS Karagkouni D Georgakilas G Kanellos I Vergoulis T et al DI-ANA-LncBase v2: indexing microRNA targets on non-coding transcripts Nucleic Acids Res 2016 44D1D231 810.1093/nar/gkv1270470289726612864Search in Google Scholar

25Li JH, Liu S, Zhou H, Qu LH, Yang JH. StarBase v2.0: Decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res. 2014; 42(Database issue):D92-7Li JH Liu S Zhou H Qu LH Yang JH StarBase v2.0: Decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data Nucleic Acids Res 2014 42Database issueD92 710.1093/nar/gkt1248396494124297251Search in Google Scholar

26Thorn CF, Klein TE, Altman RB. PharmGKB: the pharmacogenetics and pharmacogenomics knowledge base. Methods Mol Biol. 2005; 311:179-91Thorn CF Klein TE Altman RB PharmGKB: the pharmacogenetics and pharmacogenomics knowledge base Methods Mol Biol 2005 311179 9110.1385/1-59259-957-5:17916100408Search in Google Scholar

27Chen HJ, Liu J. Actein ameliorates hepatic steatosis and fibrosis in high fat diet-induced NAFLD by regulation of insulin and leptin resistant. Biomed Pharmacother. 2018; 97: 1386-1396.Chen HJ Liu J Actein ameliorates hepatic steatosis and fibrosis in high fat diet-induced NAFLD by regulation of insulin and leptin resistant Biomed Pharmacother 2018 97 1386 139610.1016/j.biopha.2017.09.09329156528Search in Google Scholar

28Pan X, Zheng M, Zou T, Liu W, Gu X, Zhang X, et al. The LEPR K109R and Q223R Might Contribute to the Risk of NAFLD: A Meta-Analysis. Curr Mol Med. 2018; 18(2): 91-99.Pan X Zheng M Zou T Liu W Gu X Zhang X et al The LEPR K109R and Q223R Might Contribute to the Risk of NAFLD: A Meta-Analysis Curr Mol Med 2018 182 91 9910.2174/156652401866618070511041229974828Search in Google Scholar

29Zhang Y, Xiang D, Hu X, Ruan Q, Wang L, Bao Z. Identification and study of differentially expressed miRNAs in aged NAFLD rats based on high-throughput sequencing. Ann Hepatol. 2020; 19(3):302-312Zhang Y Xiang D Hu X Ruan Q Wang L Bao Z Identification and study of differentially expressed miRNAs in aged NAFLD rats based on high-throughput sequencing Ann Hepatol 2020 193302 31210.1016/j.aohep.2019.12.00331899128Search in Google Scholar

30Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. 2008; 40(12): 1461-1465.Romeo S Kozlitina J Xing C Pertsemlidis A Cox D Pennacchio LA et al Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease 2008 4012 1461 146510.1038/ng.257259705618820647Search in Google Scholar

31Kozlitina J, Smagris E, Stender S, Nordestgaard BG, Cohen JCJNG. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. 2014; 46(4): 352-356.Kozlitina J Smagris E Stender S Nordestgaard BG Cohen JCJNG Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease 2014 464 352 35610.1038/ng.2901396978624531328Search in Google Scholar

32Mancina RM, Dongiovanni P, Petta S, Pingitore P, Meroni M, Rametta R, et al. The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent. 2016; 150(5): 1219-1230.e1216. Mancina RM Dongiovanni P Petta S Pingitore P Meroni M Rametta R et al The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent 2016 1505 1219 1230e121610.1053/j.gastro.2016.01.032484407126850495Search in Google Scholar

33Eslam M, Hashem AM, Leung R, Romero-Gomez M, Berg T, Dore GJ, et al. ; International Hepatitis C Genetics Consortium (IHCGC). Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease. Nat Commun. 2015; 6:6422.Eslam M Hashem AM Leung R Romero-Gomez M Berg T Dore GJ et al International Hepatitis C Genetics Consortium (IHCGC). Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease Nat Commun 2015 6642210.1038/ncomms7422436652825740255Search in Google Scholar

34Petta S, Valenti L, Marra F, Grimaudo S, Tripodo C, Bugianesi E, et al. MERTK rs4374383 polymorphism affects the severity of fibrosis in non-alcoholic fatty liver disease. 2016; 64(3): 682-690.Petta S Valenti L Marra F Grimaudo S Tripodo C Bugianesi E et al MERTK rs4374383 polymorphism affects the severity of fibrosis in non-alcoholic fatty liver disease 2016 643 682 69010.1016/j.jhep.2015.10.01626596542Search in Google Scholar

35Aller R, De Luis DA, Izaola O, González Sagrado M, Conde R, Pacheco D, et al. Lys656Asn polymorphism of leptin receptor, leptin levels and insulin resistance in patients with non alcoholic fatty liver disease. Eur Rev Med Pharmacol Sci. 2012;16(3):335-41.Aller R De Luis DA Izaola O González Sagrado M Conde R Pacheco D et al Lys656Asn polymorphism of leptin receptor, leptin levels and insulin resistance in patients with non alcoholic fatty liver disease Eur Rev Med Pharmacol Sci 2012163335 41Search in Google Scholar

36An BQ, Lu LL, Yuan C, Xin YN, Xuan SY. Leptin Receptor Gene Polymorphisms and the Risk of Non-Alcoholic Fatty Liver Disease and Coronary Atherosclerosis in the Chinese Han Population. Hepat Mon. 2016; 16(4):e35055.An BQ Lu LL Yuan C Xin YN Xuan SY Leptin Receptor Gene Polymorphisms and the Risk of Non-Alcoholic Fatty Liver Disease and Coronary Atherosclerosis in the Chinese Han Population Hepat Mon 2016 164e3505510.5812/hepatmon.35055488849927257426Search in Google Scholar

37Neville LF, Mathiak G, Bagasra O. The immunobiology of interferon-gamma inducible protein 10 kD (IP-10): a novel, pleiotropic member of the C-X-C chemokine superfamily. Cytokine Growth Factor Rev. 1997; 8(3):207-19.Neville LF Mathiak G Bagasra O The immunobiology of interferon-gamma inducible protein 10 kD (IP-10): a novel, pleiotropic member of the C-X-C chemokine superfamily Cytokine Growth Factor Rev 1997 83207 1910.1016/S1359-6101(97)00015-49462486Search in Google Scholar

38Luster AD, Unkeless JC, Ravetch JV. Gamma-interferon transcriptionally regulates an early-response gene containing homology to platelet proteins. Nature. 1985; 315(6021):672-6.Luster AD Unkeless JC Ravetch JV Gamma-interferon transcriptionally regulates an early-response gene containing homology to platelet proteins Nature 1985 3156021672 610.1038/315672a03925348Search in Google Scholar

39Bertola A, Bonnafous S, Anty R, Patouraux S, Saint-Paul MC, Iannelli A, et al. Hepatic expression patterns of inflammatory and immune response genes associated with obesity and NASH in morbidly obese patients. PLoS One. 2010; 5(10):e13577.Bertola A Bonnafous S Anty R Patouraux S Saint-Paul MC Iannelli A et al Hepatic expression patterns of inflammatory and immune response genes associated with obesity and NASH in morbidly obese patients PLoS One 2010 510e1357710.1371/journal.pone.0013577296265121042596Search in Google Scholar

40Zhang X, Shen J, Man K, Chu ES, Yau TO, Sung JC, et al. CXCL10 plays a key role as an inflammatory mediator and a non-invasive biomarker of non-alcoholic steatohepatitis. Journal of hepatology. 2014; 61(6): 1365-1375.Zhang X Shen J Man K Chu ES Yau TO Sung JC et al CXCL10 plays a key role as an inflammatory mediator and a non-invasive biomarker of non-alcoholic steatohepatitis Journal of hepatology 2014 616 1365 137510.1016/j.jhep.2014.07.00625048951Search in Google Scholar

41Dong XC, Copps KD, Guo S, Li Y, Kollipara R, Depinho RA, et al. Inactivation of Hepatic Foxo1 by Insulin Signaling Is Required for Adaptive Nutrient Homeostasis and Endocrine Growth Regulation. 2008; 8(1): 0-76.Dong XC Copps KD Guo S Li Y Kollipara R Depinho RA et al Inactivation of Hepatic Foxo1 by Insulin Signaling Is Required for Adaptive Nutrient Homeostasis and Endocrine Growth Regulation 2008 81 0 7610.1016/j.cmet.2008.06.006292966718590693Search in Google Scholar

42Munekata K, Sakamoto K. Forkhead transcription factor Foxo1 is essential for adipocyte differentiation. In Vitro Cell Dev Biol Anim. 2009; 45(10):642-51.Munekata K Sakamoto K Forkhead transcription factor Foxo1 is essential for adipocyte differentiation In Vitro Cell Dev Biol Anim 2009 4510642 5110.1007/s11626-009-9230-519585174Search in Google Scholar

43Li Y, Ma Z, Jiang S, Hu W, Li T, Di S, et al. A global perspective on FOXO1 in lipid metabolism and lipid-related diseases. Prog Lipid Res. 2017; 66: 42-49.Li Y Ma Z Jiang S Hu W Li T Di S et al A global perspective on FOXO1 in lipid metabolism and lipid-related diseases Prog Lipid Res 2017 66 42 4910.1016/j.plipres.2017.04.00228392404Search in Google Scholar

44Xin Z, Ma Z, Hu W, Jiang S, Yang Z, Li T, et al. FOXO1/3: Potential suppressors of fibrosis. Ageing Res Rev. 2018; 41: 42-52.Xin Z Ma Z Hu W Jiang S Yang Z Li T et al FOXO1/3: Potential suppressors of fibrosis Ageing Res Rev 2018 41 42 5210.1016/j.arr.2017.11.00229138094Search in Google Scholar

45Valenti L, Dongiovanni P, Rametta R, Fracanzani AL, Fargion SJD, Disease L. FOXO1 genotype influences the susceptibility to and severity of NAFLD by modulating FOXO1 expression. 2009; 41(3):A2–A3.Valenti L Dongiovanni P Rametta R Fracanzani AL Fargion SJD Disease L FOXO1 genotype influences the susceptibility to and severity of NAFLD by modulating FOXO1 expression 2009 413A2 A310.1016/j.dld.2008.12.010Search in Google Scholar